WO2016191695A3 - Traitements d'infections intracellulaires strictes - Google Patents
Traitements d'infections intracellulaires strictes Download PDFInfo
- Publication number
- WO2016191695A3 WO2016191695A3 PCT/US2016/034686 US2016034686W WO2016191695A3 WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3 US 2016034686 W US2016034686 W US 2016034686W WO 2016191695 A3 WO2016191695 A3 WO 2016191695A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatments
- intracellular infections
- obligately intracellular
- infections
- obligately
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions et des procédés utilisés pour le traitement d'infections bactériennes, par exemple d'infections par bactéries intracellulaires strictes. Selon certains modes de réalisation, un inhibiteur de Wnt peut être administré à un sujet mammifère pour traiter l'ehrlichiose
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167669P | 2015-05-28 | 2015-05-28 | |
US62/167,669 | 2015-05-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016191695A2 WO2016191695A2 (fr) | 2016-12-01 |
WO2016191695A3 true WO2016191695A3 (fr) | 2017-01-05 |
Family
ID=56133065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/034686 WO2016191695A2 (fr) | 2015-05-28 | 2016-05-27 | Traitements d'infections intracellulaires strictes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016191695A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019126739A1 (fr) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Thérapies anti-cancer à base de pamoate de pyrvinium |
US20220117920A1 (en) * | 2019-02-14 | 2022-04-21 | University Of Kentucky Research Foundation | N-Aryl Benzenesulfonamides as Protonophores for the Treatment of Cancers, Metabolic Diseases and Traumatic Brain Injury |
CN112933066B (zh) * | 2021-02-26 | 2023-05-02 | 河南省农业科学院 | 抑制剂kn-93抑制猪繁殖与呼吸综合征病毒体外感染的方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130323284A1 (en) * | 2012-06-05 | 2013-12-05 | Jazzya Investments | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION |
-
2016
- 2016-05-27 WO PCT/US2016/034686 patent/WO2016191695A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130323284A1 (en) * | 2012-06-05 | 2013-12-05 | Jazzya Investments | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION |
Non-Patent Citations (8)
Title |
---|
BAI XIYUAN ET AL: "Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of Mycobacterium tuberculosis in Human Macrophages", PLOS ONE, vol. 8, no. 4, April 2013 (2013-04-01), XP055293629 * |
DE GROOTE M A ET AL: "The Search For New Antimicrobial Agents Against Mycobacterium abscessus", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, 2012, & 52ND INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC); SAN FRANCISCO, CA, USA; SEPTEMBER 09 -12, 2012, pages F831, XP009191237, ISSN: 0733-6373 * |
DUMLER J STEPHEN ET AL: "Ehrlichioses in humans: Epidemiology, clinical presentation, diagnosis, and treatment", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 45, no. Suppl. 1, 15 July 2007 (2007-07-15), pages S45 - S51, XP002498681, ISSN: 1058-4838, DOI: 10.1086/518146 * |
FLORES R ET AL: "Chlamydia pneumoniae Inclusion Membrane Protein Cpn1027 Interacts with Caprin 2 Enhancing the Canonical Wnt Signaling Pathway", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 110, 2010, & 110TH GENERAL MEETING OF THE AMERICAN-SOCIETY-FOR-MICROBIOLOGY; SAN DIEGO, CA, USA; MAY 23 -27, 2010, pages B - 055, XP055293653, ISSN: 1060-2011 * |
KESSLER MIRJANA ET AL: "Chlamydia trachomatis Disturbs Epithelial Tissue Homeostasis in Fallopian Tubes via Paracrine Wnt Signaling", AMERICAN JOURNAL OF PATHOLOGY, vol. 180, no. 1, January 2012 (2012-01-01), pages 186 - 198, XP055293648 * |
LUO TIAN ET AL: "Ehrlichia chaffeensis Exploits Canonical and Noncanonical Host Wnt Signaling Pathways To Stimulate Phagocytosis and Promote Intracellular Survival", INFECTION AND IMMUNITY, vol. 84, no. 3, March 2016 (2016-03-01), pages 686 - 700, XP009191238 * |
SENDIDE KHALID ET AL: "Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: Regulation by phosphatidylinositol 3-kinase and cytohesin-1", JOURNAL OF IMMUNOLOGY, vol. 174, no. 7, April 2005 (2005-04-01), pages 4210 - 4219, XP055293620, ISSN: 0022-1767 * |
WAKEEL A ET AL: "New insights into molecular Ehrlichia chaffeensis-host interactions", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 12, no. 5, 1 May 2010 (2010-05-01), pages 337 - 345, XP027011818, ISSN: 1286-4579, [retrieved on 20100129] * |
Also Published As
Publication number | Publication date |
---|---|
WO2016191695A2 (fr) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015114666A3 (fr) | Traitements pour l'acné résistante | |
PH12017501646A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2013184755A3 (fr) | Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation | |
MY173518A (en) | Antimicrobial compounds and methods of making and using the same | |
PH12016502092A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2016179440A3 (fr) | Thérapie antimicrobienne | |
PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
WO2015148863A3 (fr) | Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose | |
PH12016500453A1 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2017083431A3 (fr) | Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes | |
MX2013012165A (es) | Composicion y metodo para mejorar una respuesta inmune. | |
NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MY176900A (en) | Antimicrobial compounds and methods of making and using the same | |
WO2016210384A3 (fr) | Bactéries manipulées pour traiter des maladies métaboliques | |
MX2016010451A (es) | Benzoxaboroles microbicidamente activos. | |
WO2019040106A3 (fr) | Composés, sels associés et méthodes pour le traitement de maladies | |
WO2015110969A3 (fr) | Composés contenant de l'azote et leur utilisation | |
AU2015352440B2 (en) | Compounds | |
EP3268010A4 (fr) | Compositions et méthodes de traitement d'une infection bactérienne | |
MX2017006674A (es) | Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies. | |
MX363631B (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
MY161870A (en) | Antimicrobial compounds and methods of making and using the same | |
WO2013166282A3 (fr) | Procédés et compositions pour traiter une infection bactérienne | |
WO2016191695A3 (fr) | Traitements d'infections intracellulaires strictes | |
EP3190893A4 (fr) | Compositions et procédés de traitement et de prévention d'infections bactériennes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16729696 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16729696 Country of ref document: EP Kind code of ref document: A2 |